Status:
COMPLETED
Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
This observational study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in subjects with type 2 diabetes during Levemir® treatment.
Eligibility Criteria
Inclusion
- Any patient with type 2 diabetes
- Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin)
- Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient
Exclusion
- Known or suspected allergy to study product(s) or related products.
- Pregnancy or breastfeeding or intention of becoming pregnant within the next 6 months
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
314 Patients enrolled
Trial Details
Trial ID
NCT00735501
Start Date
March 1 2008
End Date
May 1 2010
Last Update
October 29 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Copenhagen S, Denmark, 2300
2
Stockholm, Sweden, 182 88